COST

1,010.1

+1.84%↑

PG

162.42

+2.84%↑

KO

71.62

+3.6%↑

PM

169.23

+3.24%↑

PEP

131.4

+2.3%↑

COST

1,010.1

+1.84%↑

PG

162.42

+2.84%↑

KO

71.62

+3.6%↑

PM

169.23

+3.24%↑

PEP

131.4

+2.3%↑

COST

1,010.1

+1.84%↑

PG

162.42

+2.84%↑

KO

71.62

+3.6%↑

PM

169.23

+3.24%↑

PEP

131.4

+2.3%↑

COST

1,010.1

+1.84%↑

PG

162.42

+2.84%↑

KO

71.62

+3.6%↑

PM

169.23

+3.24%↑

PEP

131.4

+2.3%↑

COST

1,010.1

+1.84%↑

PG

162.42

+2.84%↑

KO

71.62

+3.6%↑

PM

169.23

+3.24%↑

PEP

131.4

+2.3%↑

Search

Hims & Hers Health Inc

Cerrado

SectorConsumo defensivo

58.5 -4.75

Resumen

Variación precio

24h

Actual

Mínimo

53.83

Máximo

62.59

Métricas clave

By Trading Economics

Ingresos

23M

49M

Ventas

105M

586M

P/B

Media del Sector

81.191

42.52

BPA

0.2

Margen de beneficios

8.444

Empleados

1,637

EBITDA

39M

58M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-28.84% downside

Dividendos

By Dow Jones

Próximas Ganancias

4 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

3.2B

12B

Apertura anterior

63.25

Cierre anterior

58.5

Noticias sobre sentimiento de mercado

By Acuity

20%

80%

16 / 151 Clasificación en Consumer defensive

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Hims & Hers Health Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 abr 2025, 12:54 UTC

Principales Movimientos del Mercado

Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

4 abr 2025, 22:38 UTC

Acciones populares

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1 abr 2025, 23:15 UTC

Principales Movimientos del Mercado

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25 feb 2025, 15:33 UTC

Principales Movimientos del Mercado

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18 nov 2024, 19:07 UTC

Principales Movimientos del Mercado

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14 oct 2024, 15:02 UTC

Principales Movimientos del Mercado

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3 oct 2024, 11:28 UTC

Principales Movimientos del Mercado

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

7 may 2025, 13:56 UTC

Ganancias

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

6 may 2025, 14:24 UTC

Ganancias

Hims & Hers Stock Is Higher After Earnings. The Sales Outlook Looks Low. -- Barrons.com

30 abr 2025, 09:30 UTC

Principales Noticias

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

2 abr 2025, 16:53 UTC

Principales Noticias

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19 mar 2025, 15:54 UTC

Principales Noticias

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21 feb 2025, 23:20 UTC

Ganancias

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10 feb 2025, 12:00 UTC

Principales Noticias

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19 dic 2024, 17:16 UTC

Principales Noticias

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 dic 2024, 15:14 UTC

Principales Noticias

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19 dic 2024, 15:02 UTC

Principales Noticias

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16 dic 2024, 13:47 UTC

Principales Noticias

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16 dic 2024, 07:00 UTC

Principales Noticias

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3 oct 2024, 14:45 UTC

Principales Noticias

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3 oct 2024, 13:12 UTC

Principales Noticias

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 oct 2024, 11:45 UTC

Principales Noticias

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 oct 2024, 10:14 UTC

Principales Noticias

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2 ago 2024, 17:52 UTC

Adquisiciones, fusiones, absorciones

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26 jun 2024, 11:00 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

24 may 2024, 20:37 UTC

Ganancias

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Comparación entre iguales

Cambio de precio

Hims & Hers Health Inc previsión

Precio Objetivo

By TipRanks

-28.84% descenso

Estimación a 12 Meses

Media 45.54 USD  -28.84%

Máximo 85 USD

Mínimo 25 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hims & Hers Health Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

14 ratings

4

Comprar

8

Mantener

2

Vender

Puntuación técnica

By Trading Central

36.685 / 52.35Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

16 / 151 Clasificación en Consumo defensivo

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.